We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Review of Urate-Lowering Therapeutics: From the Past to the Future.
- Authors
Jenkins, Christopher; Hwang, Jennifer H.; Kopp, Jeffrey B.; Winkler, Cheryl A.; Sung Kweon Cho
- Abstract
We reviewed all currently available ULT, as well as any medications in development using following databases: United States Food and Drug Administration (FDA), European Medicines Agency (EMA), Japanese Pharmaceutical and Medical Devices Agency (PMDA), and ClinicalTrials.gov. We identified a total of 36 drugs, including 10 approved drugs, 17 in clinical testing phases, and 9 in preclinical developmental phases. The 26 drugs currently undergoing testing and development include 5 xanthine oxidase inhibitors, 14 uricosurics, 6 recombinant uricases, and one with multiple urate-lowering mechanisms of action. Herein, we reviewed the benefit and risk of each drug summarizing currently available drugs. New trials of uricosuric agents are underway to develop the new indication. New drugs are going on to improve the potency of recombinant uricase and to develop the new route administration of such as oral formulation. This review will provide valuable information on the properties, indications, and limitations of ULTs.
- Subjects
EUROPEAN Medicines Agency; UNITED States. Food &; Drug Administration; XANTHINE oxidase; ORAL drug administration; MEDICAL equipment; NEW trials; THERAPEUTICS
- Publication
Frontiers in Pharmacology, 2022, Vol 13, p1
- ISSN
1663-9812
- Publication type
Article
- DOI
10.3389/fphar.2022.925219